MedTrace Logo

Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells

NCT04105582 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-06-21

No results posted yet for this study

Summary

In this project, the investigators propose the first clinical study in Colombia of vaccination of patients with triple-negative breast cancer (TNBC) using synthetic peptides that contain mutations of the tumor itself that will be presented to the immune system by autologous dendritic cells to assess immunogenicity and safety of this type of personalized vaccine. Achieving the specific objectives set out in this project will mean that the investigators can validate in Colombia the experimental design necessary to identify exclusive epitopes in the tumors of the participants in this study, and also that have been able to demonstrate the safety and immunogenicity of these vaccines.

Conditions

Interventions

BIOLOGICAL

Neo-antigen pulsed Dendritic cell

Patients that have already finished their conventional treatment (chemotherapy and/or surgery) will be vaccinated with dendritic cells pulsed with synthetic peptide

Sponsors & Collaborators

  • Fundación Salud de los Andes

    collaborator OTHER

  • Universidad Nacional de Colombia

    lead OTHER

Principal Investigators

  • Carlos A Parra-Lopez, MD PhD · Full Professor School of Medicine. Microbiology Department.

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2020-12-01
Completion
2022-02-01

Countries

  • Colombia

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04105582 on ClinicalTrials.gov